Targets › PLASMODIUM
3 programs from 2 companies in 3 trials: 3 Phase 4; Infectious disease; next expected readout Dec 2027.
Open in Phaseline: the race on PLASMODIUM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Yale University | Artemether-lumefantrine (AL) Artemisinin derivative and aminoquinoline antimalarial combination | PLASMODIUM | Phase 4 | Malaria | Dec 2027 |
| Yale University | Artesunate-amodiaquine (AS-AQ) Artemisinin derivative and aminoquinoline antimalarial combination | PLASMODIUM | Phase 4 | Malaria | Dec 2027 |
| University of Oxford | DHA/piperaquine and SLD-PQ Artemisinin derivative and quinoline antimalarial | PLASMODIUM | Phase 4 | Plasmodium Falciparum Malaria | Feb 2028 |
Malaria (2) Plasmodium Falciparum Malaria (1)
small molecule (2), mixed (1)
Yale University (2) University of Oxford (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.